Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 127 publications
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 20, 2026
New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.
Journal: Breast (Edinburgh, Scotland)
Published: April 08, 2026
Reply to Letter to the Editor "The curious incident of the T-DXd alone arm killed at (DESTINY-Breast) eleven o'clock" by Orlandi.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 06, 2026
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.
Journal: Clinical breast cancer
Published: February 19, 2026
Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 08, 2026
Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States.
Journal: Breast (Edinburgh, Scotland)
Published: October 16, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 15, 2025
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 03, 2025
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan.
Journal: JCO precision oncology
Published: May 29, 2025
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: May 23, 2025
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.
Journal: Cancer discovery
Published: April 15, 2025
Last Updated: 09/26/2026